A second patent in a chain falls to obviousness-type double patenting challenge

by Robins Kaplan LLP

Abbvie Inc., et al. v. Kennedy Trust for Rheumatology Research

Case Number: 1:13-cv-01358-PAC

The court had previously determined that The Kennedy Trust’s U.S. Patent No. 7,846,442 (the “parent patent”) was invalid for obviousness-type double patenting (“ODP”) to U.S. Patent No. 6,270,766 (“the grandparent“). At issue in this case was whether U.S. Patent No. 8,383,120 (“the ´120 patent“) is similarly invalid. The ´120 patent is a continuation of the parent patent.

Judge Crotty found that, at summary judgment, collateral estoppel applied here, and that the ´120 patent is invalid. While he refused to simply compare the claims of the ´120 patent to the claims of the parent patent, when he considered the differences between the ´120 patent and the grandparent, he found no patentable distinction. Prior determinations of ODP are preclusive, he said, when “the differences revealed by a comparison of the claims do not vary the relevant issues bearing on obviousness.” The patentee, the court said, offered three grounds under which the claims of the ´120 patent were not obvious under the grandparent’s claims:

  • The ´120 patent defines the “disease activity element” in a manner that is “substantially more specific, specifically requiring ‘the presence of six or more swollen joints plus at least three of the following four secondary criteria. . .’”
  • The ´120 patent “require[s] a specific level of therapeutic benefit . . . greater than fifty percent (50%) according to the Paulus criteria for a significant duration of time,” whereas the parent patent claims require only “reduction of the signs and symptoms of the disease [rheumatoid arthritis]”
  • The ´120 patent claims explicitly recite the biological mechanism by which the claimed antibody must act, whereas the parent patent’s claims were not so explicit

Turning first to the “disease activity element,” the court characterized this as the level of disease in the patient population. In the prior litigation, the court had already rejected the argument that it would be nonobvious to treat sicker patients. Accordingly, the new limitation of the ´120 patent, which is directed to patients having more rather than less disease, was not non-obvious.

The court characterized the second limitation, requiring a specific level of benefit, as the “treatments benefit.” At the prior trial, the court had already heard evidence relating to treatments benefit as measured by the Paulus criteria. There, the court found no unexpected results. As “[m]erely discovering and claiming a new benefit of an old process cannot render the process again patentable,” (King Pharm., Inc. v. Eon Labs, Inc., 616 F.3d 1267, 1275 (Fed. Cir. 2010)), the new limitation was not non-obvious.

Finally, with respect to the newly-claimed biological mechanism, the court made two findings, each of which it said made the element not non-obvious. First, the patentee pointed to one reference and said that the mechanism “was not established in this study.” Failing to allege that the mechanism was not known (rather than that it was not known to one author) failed to raise a genuine issue of fact. Second, the court found that the claimed mechanism is inherent, and that “[m]erely describing an inherent property or mechanism of the prior art, without more, does not render a claim patentably distinct.” Alcon Research, Ltd. v. Apotex Inc., 687 F.3d 1362, 1369 (Fed. Cir. 2012).

In finding the ´120 patent invalid, the court summarized its position as follows:

Taking the differences between the ´120 Patent and the [parent patent] in the context of their importance to the invention as a whole, it is clear that they raise no new issue bearing on the ODP analysis. Not only does the ´120 Patent merely limit its claims to those that were already clearly covered by the prior two patents, it has done so in ways that the Court actually considered in the Prior Action. A patentee like Kennedy may seek to adjust its claims in response to actions by a patent examiner or by a court, but Kennedy has failed to do so here in any way that would materially affect the Court’s prior ODP analysis. In essence, Kennedy has claimed the same treatment as a new invention—but with limitations to treat sicker patients, for a specific outcome, and by a specific mechanism that was inherent in the prior art. As with the narrowed claims of the [parent patent], this is precisely the kind of insubstantial tinkering on a previous patent that the ODP doctrine renders unpatentable.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Robins Kaplan LLP | Attorney Advertising

Written by:

Robins Kaplan LLP

Robins Kaplan LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.